Prognose
Analytikernes gennemsnitlige kursmål er 93,77 € (+82,29 %). Medianen er 94,78 € (+84,25 %).
| Køb |
18 |
| Behold |
6 |
| Sælg |
2 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
PTC Therapeutics raises forecast – Wells Fargo sees 74% upside potential from Sephience
PTC Therapeutics reports robust sales driven by the drug Sephience and raises its full-year forecast. Wells Fargo reaffirms its buy rating and sets a price target of $112, implying roughly 74% upside. Management says Sephience’s market penetration is proceeding as planned. » Mere på finanzen.net
PTC Therapeutics: SEPHIENCE drives revenue momentum, cash-flow breakeven targeted for 2026
At the Cantor Healthcare Conference PTC Therapeutics reported a strong SEPHIENCE launch in PKU with over 2,000 therapy-start applications in the U.S. and a global revenue potential of more than $2 billion. The company shows over $2 billion in cash and expects cash-flow breakeven in 2026. Phase‑2 data for votoplam in Huntington’s chorea demonstrated a 52% slowing of disease progression at the higher dose; a Phase‑3 study is already ongoing. PTC is also acquiring ST-920 for Fabry disease (upfront payment $111 million), which is in the BLA stage and could have peak sales potential of more than $750 million. » Mere på de.investing.com
PTC Therapeutics counts on SUFIANCE as growth driver and targets cash-flow breakeven in 2026
At the Wells Fargo conference PTC Therapeutics outlined its strategy: shifting away from older products toward a broader rare-disease portfolio. SUFIANCE (Pegvaliase) is driving growth, has reached all 103 US centers of excellence and is expected to offer more than $2 billion in revenue potential. Management reports more than $2 billion in cash, disciplined cost reductions and expects cash-flow breakeven in 2026. Meanwhile PTC is expanding its pipeline (including Votoplam, MSH3, Vatiquinon, NLRP3) and is acquiring the gene therapy ST-920 for Fabry disease ($100–110 million) for further diversification. » Mere på de.investing.com
PTC Therapeutics acquires gene therapy ST-920 for Fabry disease in bankruptcy auction
PTC Therapeutics purchased ST-920 from Sangamo Therapeutics in a bankruptcy auction. The deal includes an upfront payment of $111 million and up to $100 million in regulatory approval milestone payments. PTC plans to complete the BLA filing for accelerated approval in the U.S. by Q4 2026 and then pursue international approvals using its existing infrastructure. Closing remains subject to contract documentation, bankruptcy court approval and antitrust review, and is expected in late Q3/early Q4 2026. » Mere på de.investing.com
PTC Therapeutics: Sephience launch brings record sales and more than $2 billion in potential
PTC Therapeutics achieves record sales from the launch of Sephience and sees peak revenue potential of more than $2 billion. The company focuses on targeted interventions in RNA biology to treat diseases such as DMD and PKU. In addition, positive long-term data for Votoplam against Huntington triggered a $50 million milestone payment from Novartis. » Mere på finanzen.net
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalI 2013 har PTC Therapeutics allerede udloddet 0,0663 € i udbytte. Den seneste udlodning fandt sted i juni 2013.
Virksomhedstal
I det seneste kvartal havde PTC Therapeutics en omsætning på 315,89 mio. € og et nettoresultat på -45,64 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 315,89 mio. | 75,68 % |
| Bruttofortjeneste | 295 mio. | 264,15 % |
| Nettoresultat | -45,64 mio. | 436,92 % |
| EBITDA | 19,07 mio. | 8,47 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 4,3 mia. € |
Antal aktier | 83,54 mio. |
Højeste/laveste i 52 uger | 82,81 € - 51,20 € |
| Udbytte | Nej |
Beta | 0,51 |
P/E (PE Ratio) | -43,07 |
PEG (PEG Ratio) | 0,61 |
K/I (PB Ratio) | -24,63 |
P/S (PS Ratio) | 4,08 |
Virksomhedsprofil
PTC Therapeutics, Inc., et biofarmaceutisk selskab, fokuserer på opdagelse, udvikling og kommercialisering af medicin til patienter med sjældne sygdomme. Dets porteføljepipeline omfatter kommercielle produkter og produktkandidater på forskellige udviklingsstadier, herunder kliniske, prækliniske samt forsknings- og opdagelsesstadier, og fokuserer på udvikling af behandlinger inden for flere terapeutiske områder, såsom sjældne sygdomme. Selskabet tilbyder Translarna og Emflaza til behandling af Duchennes muskeldystrofi i Det Europæiske Økonomiske Samarbejdsområde og USA, samt til behandling af Duchennes muskeldystrofi forårsaget af nonsens-mutation i Brasilien og Rusland; kommercialiserer Tegsedi og Waylivra til behandling af sjældne sygdomme i Latinamerika og Caribien; og markedsfører Evrysdi til behandling af spinal muskelatrofi hos voksne og børn fra to måneders alderen i Brasilien. Selskabets splejsningsplatform omfatter PTC518, som udvikles til behandling af Huntingtons sygdom. PTC Therapeutics, Inc. har samarbejder med F. Hoffman-La Roche Ltd og Hoffman-La Roche Inc. samt Spinal Muscular Atrophy Foundation om at fremme forsknings- og udviklingsarbejde inden for lægemiddelopdagelse og regenerativ medicin; og med Akcea Therapeutics, Inc. om at kommercialisere Tegsedi og Waylivra til behandling af sjældne sygdomme i Latinamerika og Caribien. PTC Therapeutics, Inc. blev stiftet i 1998 og har hovedkontor i South Plainfield, New Jersey.
| Navn | PTC Therapeutics |
| CEO | Matthew Klein |
| Hjemsted | Warren,
nj USA |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 20.06.2013 |
| Medarbejdere | 991 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | PTCT |
Frankfurt | BH3.F |
Düsseldorf | BH3.DU |
SIX | P91.SW |
München | BH3.MU |